Important pharmaceutical group is interested in acquiring pharmaceutical companies with sales levels above USD 5 million. Companies with portfolios of generics are discarded. The buyer considers that only brands add value.
Likewise, company seeks targets with gross margin on sales above 50% and preferably in the range 65% -70% are preferred and those companies with a good number of brands in their portfolio are preferred. In addition, targets that have one or more of their own plants are considered more attractive.
Finally, it should be noted that the buyer operates in the private market, but would consider attractive a target that would allow him to operate in markets where he does not currently operate, such as: Institutional (social security) or high cost (oncology, HIV, etc.).